Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype

We should interpret carefully MRI-CR of NAC to evaluate residual disease for ER++/HER2− BC.